Published in Int J Radiat Oncol Biol Phys on April 01, 1989
Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol (2000) 5.94
Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A (1995) 2.94
Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A (1997) 2.86
Relationships between cycling hypoxia, HIF-1, angiogenesis and oxidative stress. Radiat Res (2009) 1.88
Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumours. Br J Cancer (1995) 1.39
A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment. Integr Biol (Camb) (2011) 1.24
In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6. Neoplasia (2008) 1.15
Nicotinamide, Fluosol DA and Carbogen: a strategy to reoxygenate acutely and chronically hypoxic cells in vivo. Br J Cancer (1991) 1.07
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Further evaluation of nicotinamide and carbogen as a strategy to reoxygenate hypoxic cells in vivo: importance of nicotinamide dose and pre-irradiation breathing time. Br J Cancer (1993) 0.95
Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements. Br J Cancer (1999) 0.94
Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br J Cancer (1996) 0.92
Rapid decrease in tumor perfusion following VEGF blockade predicts long-term tumor growth inhibition in preclinical tumor models. Angiogenesis (2012) 0.87
Microregional blood flow in murine and human tumours assessed using laser Doppler microprobes. Br J Cancer Suppl (1996) 0.87
Modeling the spatial distribution of chronic tumor hypoxia: implications for experimental and clinical studies. Comput Math Methods Med (2012) 0.86
Carbogen and nicotinamide in the treatment of bladder cancer with radical radiotherapy. Br J Cancer (1997) 0.85
Modification of tumour radiation response in vivo by the benzamide analogue pyrazinamide. Br J Cancer (1990) 0.83
Effects of exercise training on tumor hypoxia and vascular function in the rodent preclinical orthotopic prostate cancer model. J Appl Physiol (1985) (2013) 0.82
Suppression of HIF-1α expression and radiation resistance in acute hypoxic conditions. Exp Ther Med (2011) 0.82
Mechanisms of blood flow and hypoxia production in rat 9L-epigastric tumors. Tumor Microenviron Ther (2013) 0.81
Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent. Cancer Cell Int (2012) 0.81
Transient perfusion in human melanoma xenografts. Br J Cancer (1995) 0.80
Microvascular Perfusion Changes following Transarterial Hepatic Tumor Embolization. J Vasc Interv Radiol (2015) 0.79
Hydroethidine: a fluorescent redox probe for locating hypoxic cells in spheroids and murine tumours. Br J Cancer (1989) 0.76
The effects of carbogen and nicotinamide on intravascular oxyhaemoglobin saturations in SCCVII and KHT murine tumours. Br J Cancer (1995) 0.75
Use of thymidine analogues to indicate vascular perfusion in tumours. Br J Cancer (2000) 0.75
Drug-induced alterations in tumour perfusion yield increases in tumour cell radiosensitivity. Br J Cancer (2001) 0.75
Guidelines for the welfare and use of animals in cancer research. Br J Cancer (2010) 6.97
Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res (1990) 4.60
The comet assay: a comprehensive review. Mutat Res (1995) 3.80
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Intermittent blood flow in a murine tumor: radiobiological effects. Cancer Res (1987) 2.85
Radiation response of multicell spheroids--an in vitro tumour model. Curr Top Radiat Res Q (1976) 2.73
Expression of phosphorylated histone H2AX in cultured cell lines following exposure to X-rays. Int J Radiat Biol (2003) 2.32
Acute hypoxia in tumors: implications for modifiers of radiation effects. Int J Radiat Oncol Biol Phys (1986) 1.84
Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res (1999) 1.79
Effects of intercellular contact on repair of radiation damage. Exp Cell Res (1972) 1.76
Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res (2001) 1.75
Use of Hoechst 33342 for cell selection from multicell systems. J Histochem Cytochem (1982) 1.72
Cell selection from a murine tumour using the fluorescent probe Hoechst 33342. Br J Cancer (1985) 1.57
Cytotoxicity, Mutagenicity and DNA damage by Hoechst 33342. J Histochem Cytochem (1982) 1.56
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain. Int J Radiat Oncol Biol Phys (1987) 1.48
Pharmacokinetics, binding and distribution of Hoechst 33342 in spheroids and murine tumours. Br J Cancer (1985) 1.47
The effects of nitrobenzene derivatives on oxygen utilization and radiation response of an in vitro tumor model. Radiat Res (1976) 1.45
Drug and radiation resistance in spheroids: cell contact and kinetics. Cancer Metastasis Rev (1994) 1.42
Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res (2001) 1.32
Endogenous expression of phosphorylated histone H2AX in tumors in relation to DNA double-strand breaks and genomic instability. DNA Repair (Amst) (2006) 1.32
Factors influencing DNA migration from individual cells subjected to gel electrophoresis. Exp Cell Res (1992) 1.30
Evidence for characteristic vascular patterns in solid tumours: quantitative studies using corrosion casts. Br J Cancer (1999) 1.30
Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro. Cancer Res (1981) 1.29
Gel electrophoresis of individual cells to quantify hypoxic fraction in human breast cancers. Cancer Res (1993) 1.25
Explanation for excessive DNA single-strand breaks and endogenous repair foci in pluripotent mouse embryonic stem cells. Exp Cell Res (2008) 1.24
Flow cytometry studies of intracellular adriamycin in single cells in vitro. Cancer Res (1981) 1.22
Inhibition of DNA synthesis by nitroheterocycles. I. Correlation with half-wave reduction potential. Br J Cancer (1979) 1.22
Tumor radiosensitization by nicotinamide: a result of improved perfusion and oxygenation. Radiat Res (1989) 1.20
Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix. Cytometry B Clin Cytom (2006) 1.20
Use of a carbocyanine dye as a marker of functional vasculature in murine tumours. Br J Cancer (1989) 1.19
Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4. Cancer Res (1998) 1.19
Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res (1987) 1.18
The cytotoxicity of melphalan and its relationship to pH, hypoxia and drug uptake. Anticancer Res (1995) 1.18
Tumour blood flow changes induced by application of electric pulses. Eur J Cancer (1999) 1.17
Vinca alkaloids: anti-vascular effects in a murine tumour. Eur J Cancer (1993) 1.17
Effects of sensitizers on cell respiration: 1. Factors influencing the effects of hypoxic cell radiosensitizers on oxygen utilization of tumour and cultured mammalian cells. Br J Cancer Suppl (1978) 1.16
Mouse but not human embryonic stem cells are deficient in rejoining of ionizing radiation-induced DNA double-strand breaks. DNA Repair (Amst) (2008) 1.16
Resistance of tumor cells to chemo- and radiotherapy modulated by the three-dimensional architecture of solid tumors and spheroids. Methods Cell Biol (2001) 1.16
Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res (2000) 1.11
Chemosensitivity testing in V79 spheroids: drug delivery and cellular microenvironment. J Natl Cancer Inst (1986) 1.10
Possible mechanisms for intermittent blood flow in the murine SCCVII carcinoma. Int J Radiat Biol (1991) 1.10
Variable radiobiological responses of spheroids. Radiat Res (1980) 1.10
Detection of etoposide resistance by measuring DNA damage in individual Chinese hamster cells. J Natl Cancer Inst (1990) 1.09
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer. Ann Oncol (2011) 1.09
Microenvironmental control of gene expression: implications for tumor angiogenesis, progression, and metastasis. Semin Radiat Oncol (1998) 1.09
Targeting gene therapy to cancer: a review. Oncol Res (1997) 1.08
Growth and cellular characteristics of multicell spheroids. Recent Results Cancer Res (1984) 1.07
A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer (2010) 1.07
Microregional fluctuations in perfusion within human tumours detected using laser Doppler flowmetry. Radiother Oncol (1996) 1.06
Detection of hypoxic cells in a murine tumor with the use of the comet assay. J Natl Cancer Inst (1992) 1.05
Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer (1998) 1.05
Fluorescent nitroheterocycles for identifying hypoxic cells. Cancer Res (1983) 1.04
Intermittent blood flow in the KHT sarcoma--flow cytometry studies using Hoechst 33342. Br J Cancer (1990) 1.04
Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer (2001) 1.03
Effects of sensitizers on cell respiration: III. The effects of hypoxic cell radiosensitizers on oxidative metabolism and the radiation response of an in vitro tumour model. Br J Cancer Suppl (1978) 1.03
Hypoxic cells in an in vitro tumour model. Int J Radiat Biol Relat Stud Phys Chem Med (1973) 1.02
Radiosensitization by nicotinamide in vivo: a greater enhancement of tumor damage compared to that of normal tissues. Radiat Res (1987) 1.01
Mutagen screening with bacteria: niridazole and nitrofurans. Mutat Res (1975) 1.01
Cell killing, radiosensitization and cell cycle redistribution induced by chronic hypoxia. Int J Radiat Oncol Biol Phys (1984) 1.01
Cytotoxicity and DNA damage to mammalian cells by nitrofurans. Chem Biol Interact (1977) 1.00
Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide. Br J Cancer (2000) 0.99
Effects of hyperthermia on the cycling, noncycling, and hypoxic cells of irradiated and unirradiated multicell spheroids. Radiat Res (1978) 0.99
Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res (2001) 0.99
Histological evidence for nonperfused vasculature in a murine tumor following hydralazine administration. Int J Radiat Oncol Biol Phys (1989) 0.98
Inhibition of DNA synthesis by nitroheterocycles. II. Mechanisms of cytotoxicity. Br J Cancer (1979) 0.98
Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer (1995) 0.98
Rejoining of DNA single- and double-strand breaks in human white blood cells exposed to ionizing radiation. Int J Radiat Biol (1998) 0.98
Measurements of relative biological effectiveness of the 70 MeV proton beam at TRIUMF using Chinese hamster V79 cells and the high-precision cell sorter assay. Radiat Res (1996) 0.98
Radioprotection of human cell nuclear DNA by polyamines: radiosensitivity of chromatin is influenced by tightly bound spermine. Radiat Res (1999) 0.98
Activation of radiosensitizers by hypoxic cells. Br J Cancer Suppl (1978) 0.98
Tumour response to hypercapnia and hyperoxia monitored by FLOOD magnetic resonance imaging. NMR Biomed (1999) 0.97
Use of a cell sorter for assays of cell clonogenicity. Cancer Res (1986) 0.97
Radiosensitization in vivo: a study with an homologous series of 2-nitroimidazoles. Int J Radiat Biol Relat Stud Phys Chem Med (1983) 0.97
The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability. Cancer Res (2001) 0.97
Effect of vascular marker Hoechst 33342 on tumour perfusion and cardiovascular function in the mouse. Br J Cancer (1990) 0.97
Analysis of DNA damage in individual cells. Methods Cell Biol (2001) 0.97
Radioprotection by WR-2721 in vitro at low oxygen tensions: implications for its mechanisms of action. Br J Cancer (1983) 0.96
Combination of nicotinamide and hyperthermia to eliminate radioresistant chronically and acutely hypoxic tumor cells. Cancer Res (1990) 0.96
Distribution of Photofrin between tumour cells and tumour associated macrophages. Br J Cancer (1991) 0.96
Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. Radiother Oncol (1999) 0.95